Potent AMA1-specific human monoclonal antibody against Plasmodium vivax Pre-erythrocytic and Blood Stages

Archive ouverte

Winnicki, Anna, C | Dietrich, Melanie, H | Yeoh, Lee, M | Carias, Lenore, L | Roobsoong, Wanlapa | Drago, Chiara, L | Malachin, Alyssa, N | Redinger, Karli, R | Feufack-Donfack, Lionel Brice | Baldor, Lea | Jung, Nicolai, C | Mclaine, Olivia, S | Skomorovska-Prokvolit, Yelenna | Orban, Agnes | Opi, D. Herbert | Kirtley, Payton | Nielson, Kiersey | Aleshnick, Maya | Zanghi, Gigliola | Rezakhani, Nastaran | Vaughan, Ashley, M | Wilder, Brandon, K | Sattabongkot, Jetsumon | Tham, Wai-Hong | Popovici, Jean | Beeson, James, G | Bosch, Jürgen | King, Christopher, L

Edité par CCSD ; Nature Publishing Group -

International audience. Abstract New therapeutics are necessary for preventing Plasmodium vivax malaria due to easy transmissibility and dormancy in the liver that increases the clinical burden due to recurrent relapse. In this manuscript we characterize 12 Pv Apical Membrane Antigen 1 (PvAMA1) specific human monoclonal antibodies from Peripheral Blood Mononuclear Cells of a Pv-exposed individual. PvAMA1 is essential for sporozoite and merozoite invasion, making it a unique therapeutic target. We show that humAb 826827 blocks the invasion of human reticulocytes using Pv clinical isolates and inhibits sporozoite invasion of human hepatocytes in vitro (IC 50 of 0.3 – 3.7 µg/mL). Inoculation of human liver transgenic (FRG-humHep) female mice with humAb 826827 significantly reduces liver infection in vivo. The crystal structure of rPvAMA1 bound to 826827 shows that 826827 partially occupies the highly conserved hydrophobic groove in PvAMA1 that binds its known receptor, RON2. We have isolated a potent humAb that is isolate-transcendent, blocks both pre-erythrocytic and blood stage infection, and could be a potential therapy for Pv.

Suggestions

Du même auteur

Human monoclonal antibodies inhibit invasion of transgenic Plasmodium knowlesi expressing Plasmodium vivax Duffy binding protein

Archive ouverte | Watson, Quentin | CCSD

International audience. Abstract Background Plasmodium vivax has been more resistant to various control measures than Plasmodium falciparum malaria because of its greater transmissibility and ability to produce late...

The PvRBP2b-TfR1 interaction is not essential for reticulocytes invasion by Plasmodium vivax isolates from Cambodia

Archive ouverte | Feufack-Donfack, Lionel, B | CCSD

International audience. Plasmodium vivax is the most widespread of the different Plasmodium species able to infect humans and is responsible for most malaria cases outside Africa. An effective, strain-transcending v...

High versus low dose of 14 days treatment of primaquine in Plasmodium vivax infected patients in Cambodia: a randomised open-label efficacy study

Archive ouverte | Eng, Virak | CCSD

Background The WHO malaria treatment guidelines recommend a total dose in the range of 3·5 to 7·0 mg/kg of primaquine to eliminate Plasmodium vivax ( P. vivax ) hypnozoites and prevent relapses. There are however indications that ...

Chargement des enrichissements...